AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.080
-0.210 (-9.17%)
At close: Nov 5, 2026, 4:00 PM EST
2.070
-0.010 (-0.48%)
After-hours: Nov 5, 2026, 4:54 PM EST
AC Immune Revenue
AC Immune had revenue of 3.24M CHF in the quarter ending September 30, 2026, with 245.47% growth. This brings the company's total for the last twelve months to 19.81M, up 353.20% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%. That makes AC Immune the 32,786th largest company in the world by revenue and 4,313th in the United States.
Revenue (ttm)
19.81M CHF
Revenue Growth
+353.20%
P/S Ratio
8.79
Revenue / Employee
162,410 CHF
Employees
122
Market Cap
206.81M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57M | -23.74M | -86.92% |
| Dec 31, 2024 | 27.31M | 12.51M | 84.51% |
| Dec 31, 2023 | 14.80M | 10.87M | 276.14% |
| Dec 31, 2022 | 3.94M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 15.43M | -95.03M | -86.03% |
| Dec 31, 2019 | 110.46M | 103.26M | 1,435.39% |
| Dec 31, 2018 | 7.19M | -13.06M | -64.48% |
| Dec 31, 2017 | 20.26M | -2.96M | -12.75% |
| Dec 31, 2016 | 23.21M | -15.88M | -40.61% |
| Dec 31, 2015 | 39.09M | 8.82M | 29.14% |
| Dec 31, 2014 | 30.27M | 21.63M | 250.46% |
| Dec 31, 2013 | 8.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Precision BioSciences | 45.04M |
| ProQR Therapeutics | 21.05M |
| Keros Therapeutics | 15.01M |
| Pyxis Oncology | 11.04M |
| Evommune | 10.00M |
| Sol-Gel Technologies | 1.80M |
| Cartesian Therapeutics | 1.48M |
ACIU News
- 1 day ago - AC Immune reports Q3 EPS (13c), consensus (16c) - TheFly
- 1 day ago - AC Immune Third Quarter 2026 Financial and Corporate Update - GlobeNewsWire
- 1 day ago - AC Immune Earnings release: Q3 2026 - Filings
- 5 weeks ago - AC Immune Slides: Investor presentation - Filings
- 6 weeks ago - AC Immune Transcript: Study result - Transcripts
- 6 weeks ago - AC Immune Press release: Study result - Filings
- 6 weeks ago - AC Immune Slides: Study result - Filings
- 6 weeks ago - AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints - TheFly